ICU (SeaStar Medical Holding) Research & Development: $7.43 Mil (TTM As of Mar. 2026)


ICU SeaStar Medical Holding Corp ICU
29 GF Score
Price $2.98
! 4 Warning Signs
View Full Analysis

What is SeaStar Medical Holding Research & Development?

SeaStar Medical Holding ICU -3.40% 29 Research & Development is $7.43 Mil as of Mar. 2026. GuruFocus rates ICU with a GF Score™ of 29/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. SeaStar Medical Holding's Research & Development for the three months ended in Mar. 2026 was $2.34 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $7.43 Mil.

SeaStar Medical Holding  (NAS:ICU) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

SeaStar Medical Holding Research & Development Related Terms

SeaStar Medical Holding Research & Development Historical Data

* Premium members only.

The historical data trend for SeaStar Medical Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SeaStar Medical Holding Research & Development Chart

SeaStar Medical Holding Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 2.77 2.50 5.97 9.11 7.52

SeaStar Medical Holding Quarterly Data
Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.43 1.04 1.85 2.20 2.34
ICU
29GF Score
SeaStar Medical Holding Corp ICU
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SeaStar Medical Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $7.43 Mil mean?
SeaStar Medical Holding (ICU) has a Research & Development of $7.43 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on SeaStar Medical Holding and its competitors.
Is SeaStar Medical Holding's Research & Development too high?
SeaStar Medical Holding's current Research & Development is $7.43 Mil. Overall, SeaStar Medical Holding has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does SeaStar Medical Holding's Research & Development compare to MBRX and LEXX?
SeaStar Medical Holding's Research & Development of $7.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on SeaStar Medical Holding and its competitors. SeaStar Medical Holding's current Research & Development is $7.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SeaStar Medical Holding stock overvalued right now?
SeaStar Medical Holding (ICU) has a current Research & Development of $7.43 Mil. The current Research & Development is $7.43 Mil. SeaStar Medical Holding's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For SeaStar Medical Holding (ICU), the current Research & Development is $7.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SeaStar Medical Holding Business Description

Address 3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
29GF Score

Get the complete analysis for ICU

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.98
Price